Detalhe da pesquisa
1.
Minimal Clinically Important Differences in 6-Minute Walk Test in Patients With HFrEF and Iron Deficiency.
J Card Fail
; 29(5): 760-770, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36332897
2.
Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial.
Cardiovasc Diabetol
; 22(1): 215, 2023 08 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37592272
3.
Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma.
J Allergy Clin Immunol
; 138(1): 142-149.e8, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-26915674
4.
Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
Lancet
; 385(9971): 857-66, 2015 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-25684586
5.
Randomized Double-Blind Controlled Trial of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease.
Am J Respir Crit Care Med
; 196(5): 656-659, 2017 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28146642
6.
Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency.
Eur J Heart Fail
; 24(5): 821-832, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35279929
7.
Responder analysis for improvement in 6-min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency.
Eur J Heart Fail
; 24(5): 833-842, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35334136
8.
Roflumilast in Asian patients with COPD: A randomized placebo-controlled trial.
Respirology
; 16(8): 1249-57, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21848706
9.
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.
Lancet
; 374(9691): 685-94, 2009 Aug 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-19716960
10.
Control of moderate-to-severe asthma with randomized ciclesonide doses of 160, 320 and 640 µg/day.
J Asthma Allergy
; 10: 35-46, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28331346
11.
Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD.
Respir Med
; 108(2): 366-75, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24120253
12.
Roflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group study.
Chest
; 145(1): 44-52, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24135893
13.
Efficacy of roflumilast in the COPD frequent exacerbator phenotype.
Chest
; 143(5): 1302-1311, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23117188
14.
Cardiovascular safety in patients receiving roflumilast for the treatment of COPD.
Chest
; 144(3): 758-765, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23412642
15.
Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol.
Int J Chron Obstruct Pulmon Dis
; 7: 375-82, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22791991
17.
Auto-ADP-ribosylation of Pseudomonas aeruginosa ExoS.
J Biol Chem
; 277(14): 12082-8, 2002 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-11821389